GLP-1 & compounded medication availability in North Carolina (2026)

North Carolina is the quietest state of our first five, a demand-driven pick whose regulators track the federal framework rather than layering on state-specific positions. All four core OrderlyMeds lines ship here, as do four of the five research peptides, and the two lines we do not carry are listed as plainly as the eight we do.

Baseline state

Availability facts last reviewed: November 16, 2026

The ten-line matrix for North Carolina

Availability of all ten OrderlyMeds product lines in North Carolina, with typical delivery times and notes
Product lineAvailable in North Carolina?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Top-five demand state for this line.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days National flat pricing applies.
NAD+ Yes 8–10 business days Standard telehealth ordering flow.
Sermorelin Yes 8–10 business days Shipped by registered partner pharmacies.
Glutathione No N/A A gap in our catalog, shown as one.
BPC-157 Yes 8–10 business days We carry it; facts below.
TB-500 Yes 8–10 business days In the catalog as a compounded injectable; section below.
KPV No N/A Not dispensed by OrderlyMeds, injectables only.
Epitalon Yes 8–10 business days Available via OrderlyMeds as a compounded injectable.
MOTS-c Yes 8–10 business days Part of our offering as a compounded injectable; own record below.

Last reviewed November 16, 2026. North Carolina gets the same honesty as the hard states: a row only says Yes when the data behind it does.

BPC-157, TB-500, KPV, Epitalon & MOTS-c: the North Carolina answer

The short answer for North Carolina is the national one: OrderlyMeds sells four of these five peptides, BPC-157, TB-500, Epitalon and MOTS-c, compounded as injectables, and sells KPV nowhere, because that line is not an injectable. The longer answer, worth reading if you are researching any of them, is the pair of cited federal facts in each section: that substance’s own FDA safety position and the compounding pathway currently covering it, which coexist, and which this page states on the lines it ships exactly as it states them on the one it does not. The five are cited separately because the five records are not the same.

BPC-157 in North Carolina

North Carolina orders for BPC-157 are filled through OrderlyMeds as a compounded injectable, under a patient-specific prescription.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in North Carolina

We dispense TB-500 to North Carolina as a compounded injectable, under a patient-specific prescription.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in North Carolina

KPV sits outside the OrderlyMeds catalog nationwide, because our peptide lines are injectables and KPV is not compounded as one.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in North Carolina

Epitalon is part of our offering in North Carolina, compounded as an injectable.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in North Carolina

MOTS-c is part of what we ship to North Carolina, compounded as an injectable. The federal record below is specific to this line rather than shared with the four above.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What North Carolina’s pharmacy regulators say about compounded medications

North Carolina rarely makes compounding news, and that is itself the finding: its rules point at the federal 503A framework and USP standards rather than at individual medications. For a patient in Charlotte or Asheville, the practical questions are the universal ones: who wrote the prescription, and which pharmacy filled it.

North Carolina's compounding rules track the federal 503A framework and USP standards; the board has published no GLP-1-specific or peptide-specific prohibition. Source: North Carolina Board of Pharmacy.

Out-of-state pharmacies shipping prescriptions to North Carolina patients must register with the board as nonresident pharmacies. Source: North Carolina Board of Pharmacy.

North Carolina permits prescribing on the basis of a telehealth encounter meeting the state's standard of care; no in-person-first requirement applies to the medications on this page. Source: Center for Connected Health Policy (CCHP) Policy Finder.

An order to a North Carolina address runs the standard OrderlyMeds flow: online eligibility, an evaluation by a provider authorized for North Carolina, fulfillment by a registered partner pharmacy, and tracked delivery inside the published 8–10 business-day window. The price is the national flat price, with no state surcharge and no dose-based step-ups, same as everywhere.

North Carolina availability FAQs

Does OrderlyMeds ship compounded GLP-1s to North Carolina?

Yes. Both compounded semaglutide and compounded tirzepatide ship to North Carolina addresses, starting at $74/month for new semaglutide customers.

Is anything about ordering different in North Carolina?

No, it is a baseline state. The regulator section above cites the registration facts that make it one.

Can I order Epitalon or KPV to a North Carolina address?

Epitalon yes, it ships as a compounded injectable, as BPC-157, TB-500 and MOTS-c do. KPV no: that line is not in our formulary in any state. Each line’s cited federal status is stated in the sections above, for all five.

How long until a North Carolina order arrives?

Plan on the published 8–10 business days from signup, tracking included.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone